NEURO-AF
Circulating Brain-derived Neurotrophic Factor (BDNF) in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training: A Pilot Study (NEURO-AF)
Sponsor study identifier
observational
200
1 country
1
Study Start
February 16, 2016
Actual (reported)Primary Completion
June 13, 2024
Actual (reported)Study Completion
June 13, 2024
Actual (reported)The main purpose of this project is to determine the impact of atrial fibrillation interventions (catheter ablation and exercise training) on circulating BDNF concentrations in patients with atrial fibrillation. It also seeks to determine if there is a relation between circulating BDNF concentrations and mental health (depression severity, quality of life and symptoms) among those undergoing interventions for atrial fibrillation catheter ablation or exercise training.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 13, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 8, 2015
Actual (reported)December 10, 2015
Actual (reported)February 16, 2016
Actual (reported)June 13, 2024
Actual (reported)June 13, 2024
Actual (reported)Changes in circulating BDNF concentrations measured by blood samples collected from subjects with atrial fibrillation
Changes in circulating BDNF concentrations measured by blood samples collected from subjects with atrial fibrillation approximately 3 months post catheter ablation or following the 12 week exercise training intervention.
approximately 3 months post catheter ablation or following the 12 week exercise training intervention period
Changes in subjects' symptoms measured by the patient diary for symptoms
approximately 3 months post catheter ablation or following the 12 week exercise training intervention period
Changes in depression severity measured using the Beck Depression Inventory II (BDI-II)
approximately 3 months post catheter ablation or following the 12 week exercise training intervention period
Changes in general quality of life as measured by the Short Form Health Survey 36 (SF-36)
approximately 3 months post catheter ablation or following the 12 week exercise training intervention period
Changes in disease specific quality of life measured by the University of Toronto Atrial Fibrillation Severity Scale (AFSS)
approximately 3 months post catheter ablation or following the 12 week exercise training intervention period
Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
Subjects with paroxysmal atrial fibrillation that will undergo catheter ablation and subjects with permanent or persistent atrial fibrillation undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y4W7, Canada
Blood samples.
Jennifer L Reed, PhD
Ottawa Heart Institute Research Corporation
Girish Nair, MD
Ottawa Heart Institute Research Corporation
First Submitted
December 8, 2015
First Posted
December 10, 2015
Study Start
February 16, 2016
Actual (reported)Primary Completion
June 13, 2024
Actual (reported)Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
June 13, 2024
Actual (reported)Last Updated
May 1, 2026
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: